Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 325 of 496 entries
View as:

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Phase: N/A Priority: Normal
NCT ID: NCT05673876 Org: User:
Start: 04/06/23 End: 01/15/24 Due: 01/15/25

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT02392624 Org: User:
Start: 05/18/15 End: 03/09/17 Due: 03/09/18

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02471846 Org: User:
Start: 07/28/15 End: 10/02/19 Due: 10/02/20

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Phase: N/A Priority: Normal
NCT ID: NCT01723826 Org: User:
Start: 12/07/12 End: 02/08/17 Due: 02/08/18

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03796013 Org: User:
Start: 01/10/19 End: 02/06/19 Due: 02/06/20

A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE)

Phase: N/A Priority: Normal
NCT ID: NCT00719472 Org: User:
Start: 07/31/08 End: 05/31/11 Due: 05/31/12

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01363947 Org: User:
Start: 06/14/11 End: 06/03/16 Due: 06/03/17

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

Phase: N/A Priority: Normal
NCT ID: NCT03606460 Org: User:
Start: 09/14/18 End: 05/31/19 Due: 05/31/20

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01437566 Org: User:
Start: 10/31/11 End: 04/30/16 Due: 04/30/17

A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable

Phase: N/A Priority: Normal
NCT ID: NCT00876122 Org: User:
Start: 03/31/08 End: 07/31/12 Due: 07/31/13

A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

Phase: N/A Priority: Normal
NCT ID: NCT00473382 Org: User:
Start: 06/30/07 End: 09/30/12 Due: 09/30/13

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT04045028 Org: User:
Start: 07/22/19 End: 03/28/23 Due: 03/28/24

A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters

Phase: N/A Priority: Normal
NCT ID: NCT00396253 Org: User:
Start: 11/30/06 End: 10/31/08 Due: 10/31/09

A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00983658 Org: User:
Start: 09/30/09 End: 01/31/11 Due: 01/31/12

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Phase: N/A Priority: Normal
NCT ID: NCT05660850 Org: User:
Start: 03/22/23 End: 10/21/24 Due: 10/21/25

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01995188 Org: User:
Start: 12/16/13 End: 11/09/16 Due: 11/09/17

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Phase: N/A Priority: Normal
NCT ID: NCT05785624 Org: User:
Start: 05/26/23 End: 08/10/27 Due: 08/10/28

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02048709 Org: User:
Start: 04/30/14 End: 02/29/16 Due: 02/28/17

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Phase: N/A Priority: Normal
NCT ID: NCT00434278 Org: User:
Start: 03/31/07 End: 11/30/08 Due: 11/30/09

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

Phase: N/A Priority: Normal
NCT ID: NCT02072226 Org: User:
Start: 05/31/14 End: 03/22/17 Due: 03/22/18

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00509769 Org: User:
Start: 07/31/07 End: 06/30/09 Due: 06/30/10

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03828747 Org: User:
Start: 01/25/19 End: 08/30/23 Due: 08/30/24

A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00676715 Org: User:
Start: 07/17/08 End: 11/08/23 Due: 11/08/24

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00097188 Org: User:
Start: 12/31/04 End: 12/31/06 Due: 12/31/07

National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00097513 Org: User:
Start: 02/28/03 End: 06/30/06 Due: 06/30/07